Renal denervation as therapy for hypertension: Potentials and unanswered questions

European Journal of Preventive Cardiology

Volumn 20, Issue 6, 2013, Pages 980-991

  Vink, Eva E ^a   Bots, Michiel L ^a   Blankestijn, Peter J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Hypertension; radioablation; renal denervation; resistant hypertension; sympathetic ablation

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATROPINE;

ADRENERGIC SYSTEM; AGE DISTRIBUTION; ANTIHYPERTENSIVE THERAPY; ATTRIBUTABLE RISK; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BRADYCARDIA; CARDIOVASCULAR CATHETER; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY DENERVATION; KIDNEY FUNCTION; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PATIENT SAFETY; PERCUTANEOUS RENAL DENERVATION; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESISTANT HYPERTENSION; REVIEW; SEX RATIO; SYSTOLIC BLOOD PRESSURE; TREATMENT INDICATION; TREATMENT OUTCOME;

HYPERTENSION; RADIOABLATION; RENAL DENERVATION; RESISTANT HYPERTENSION; SYMPATHETIC ABLATION;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG RESISTANCE; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION; KIDNEY; SYMPATHECTOMY; TREATMENT OUTCOME;

EID: 84887073138     PISSN: 20474873     EISSN: None     Source Type: Journal    
DOI: 10.1177/2047487312473019     Document Type: Review

References (32)

1. Klein IH, Ligtenberg G, Neumann J, et al. Sympathetic nerve activity is inappropriately increased in chronic renal disease. J Am Soc Nephrol. 2003 ; 14: 3239-3244
2. DiBona GF. The sympathetic nervous system and hypertension: recent developments. Hypertension. 2004 ; 43: 147-150
3. Peet MM. Hypertension and its surgical treatment by bilateral supradiaphragmatic splanchnicectomy. Am J Surg. 1948 ; 75: 48-68
4. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009 ; 373: 1275-1281
5. Pereira M, Lunet N, Azevedo A, et al. Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries. J Hypertens. 2009 ; 27: 963-975
6. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004 ; 364: 937-952
7. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005 ; 365: 217-223
8. World health report 2002: Reducing risks, promoting healthy life. Geneva, Switzerland: WHO ; 2002 :
9. Lawes CM, Vander HS, Law MR, et al. Blood pressure and the global burden of disease 2000. Part II: estimates of attributable burden. J Hypertens. 2006 ; 24: 423-430
10. World Health Organization. Preventing chronic disease: a vital investment. Geneva, Switzerland: WHO, 2005.
11. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002 ; 360: 1903-1913
12. Esler MD, Krum H, Sobotka PA, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010 ; 376: 1903-1909
13. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011 ; 57: 911-917
14. the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur J Prev Cardiol. 2012 ; 19: 585-667
15. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008 ; 51: 1403-1419
16. Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012 ; 125: 1635-1642
17. Sierra A, de la, Segura J, Banegas JR, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. J Hypertension. 2011 ; 30: 2242-2243
18. Schmieder RE, Redon J, Grassi G, et al. ESH position paper: renal denervation - an interventional therapy of resistant hypertension. J Hypertens. 2012 ; 30: 837-841
19. Mabin T, Sapoval M, Cabane V, et al. First experience with endovascular ultrasound renal denervation for the treatment of resistant hypertension. EuroIntervention. 2012 ; 8: 57-61
20. Kikuya M, Ohkubo T, Asayama K, et al. Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality: the Ohasama study. Hypertension. 2005 ; 45: 240-245
21. Dolan E, Stanton A, Thijs L, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension. 2005 ; 46: 156-161
22. Hansen TW, Jeppesen J, Rasmussen S, et al. Ambulatory blood pressure and mortality: a population-based study. Hypertension. 2005 ; 45: 499-504
23. Staessen JA, Thijs L, Fagard R, et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA. 1999 ; 282: 539-546
24. Sega R, Facchetti R, Bombelli M, et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation 111: 1777-1783.
25. Banegas JR, Messerli FH, Waeber B, et al. Discrepancies between office and ambulatory blood pressure: clinical implications. Am J Med. 2009 ; 122: 1136-1141
26. Mahfoud F, Schlaich M, Kindermann I, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation. 2011 ; 123: 1940-1946
27. Brandt MC, Mahfoud F, Reda S, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol. 2012 ; 59: 901-909
28. Hering D, Mahfoud F, Walton AS, et al. Renal denervation in moderate to severe CKD. J Am Soc Nephrol. 2012 ; 23: 1250-1257
29. Hodgson TA, Cai L. Medical care expenditures for hypertension, its complications, and its comorbidities. Med Care. 2001 ; 39: 599-615
30. Lawes CM, Rodgers A, Bennett DA, et al. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens. 2003 ; 21: 707-716
31. Geisler BP, Egan B, Cohen JT, et al. Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension. J Am Coll Cardiol. 2012 ; 60: 1271-1277
32. Hansen JM, Abildgaard U, Fogh-Andersen N, et al. The transplanted human kidney does not achieve functional reinnervation. Clin Sci. 1994 ; 87: 13-20